Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903356 | 0.99 | HTR1A (0.91) | HTR1A | |
| SCHEMBL4781671 | 0.97 | HTR1A (0.98) | HTR1A | |
| SCHEMBL4779140 | 0.89 | HTR1A (0.98) | HTR1A | |
| SCHEMBL4903903 | 0.89 | HTR1A (0.98) | HTR1A | |
| SCHEMBL4782227 | 0.87 | HTR1A (0.80) | HTR1A | |
| SCHEMBL4780274 | 0.87 | HTR1A (0.80) | HTR1A | |
| SCHEMBL4793685 | 0.85 | HTR1A (0.78) | HTR1A | |
| SCHEMBL4903834 | 0.85 | HTR1A (0.76) | HTR1A | |
| SCHEMBL4903773 | 0.85 | HTR1A (0.76) | HTR1A | |
| SCHEMBL4903750 | 0.84 | HTR1A (0.75) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | SCHWARTZ PHARMA S.L | 2008-08-21 | — | — | US | claimed |
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | SCHWARTZ PHARMA S.L | 2008-08-21 | — | — | US | disclosed |
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | SCHWARTZ PHARMA S.L | 2008-08-21 | — | — | US | disclosed |
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | SCHWARTZ PHARMA S.L | 2008-08-21 | — | — | US | disclosed |
| WO-2008015538-A2 | USE OF DIAZA- AND THIAZA-CYCLOALKANEDIONES FOR PREVENTING AND/OR TREATING PAIN AND /OR MIGRAINE | SCHWARZ PHARMA S.L. (ES) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015538-A2 | USE OF DIAZA- AND THIAZA-CYCLOALKANEDIONES FOR PREVENTING AND/OR TREATING PAIN AND /OR MIGRAINE | SCHWARZ PHARMA S.L. (ES) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | HTR1A, HTR3A, HTR2A | HTR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.